Bob Bradway
The Steward
Legacy, values and the long now, leadership as care and continuity.
Bob Bradway presents as a classic Steward, someone who frames every strategic decision through the lens of custodianship over a mission larger than commercial ambition. Throughout this interview, Bradway consistently anchors Amgen's competitive intensity, its genetic research in Iceland, its AI investments, and its pricing discipline back to patient welfare as an organizing principle.
“We need to recognize that we're in a hotly competitive field. One of the things Amgen prizes is competing intensely to win. That's not just about the effort, it's about making a difference for patients.”
On Amgen's competitive cultureundated
“The beautiful thing about our field is that we learn. We learn from failure. When we generate that final set of data and the data tell us the medicine didn't work, of course that's discouraging. But we can step back and say, what did we learn?”
On managing setbacks in drug developmentundated
“About two-thirds of our molecules in our pipeline outside of cancer are ones which we believe are genetically validated. We're pursuing them because we believe we have genetic evidence to suggest we can have a beneficial outcome.”
On genetics-driven pipeline strategyundated
Money Maze Podcast: “Biotechnology and Healthcare: A New Dawn? With Bob Bradway, CEO of Amgen”
LISTEN AT THE SOURCE ↗THE RECORD IS CHECKABLE